Based on these findings, more experiments and researches need to be done to study whether crizotinib based on ELAVL1, CBLL1, HNRNPC and RBM15B sensitize more of NSCLC cells, thus attenuating drug resistance in LC. This evidence concerns the gene RBM15B and non-small cell lung carcinoma.